LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development
Ballerup, December 16, 2020 – LEO Pharma A/S today announced that Jörg Möller will join its Global Leadership Team as Executive Vice President, Global Research and Development, effective January 1, 2021.
Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee.
A medical doctor and Ph.D. by training, Jörg Möller brings a wealth of experience from his long international career during which he was responsible for a significant global organization with main hubs in Germany, the US, Switzerland, Japan and China. He led the entire value chain from target and drug discovery through clinical development, life-cycle-management and regulatory approvals and has brought a range of successful global product approvals. His experience spans multiple therapeutic areas including dermatology and immunology and a variety of technology platforms like biologics and cell & gene therapies. He has a solid track record of working with external partners.
“Jörg Möller’s experience will help us to significantly foster our innovative pipeline which underpins our ambition to become a global leader in medical dermatology,” said Catherine Mazzacco, President and CEO of LEO Pharma.
“I am excited to join LEO Pharma and inspired by its strategy and ambition. People with dermatologic medical conditions need new treatment options, and I want to bring in my experience and expertise to the R&D team at LEO Pharma so we together can contribute significantly to improving patients’ lives,” saidJörg Möller.
Jörg Möller succeeds Kim Kjøller who, as previously announced, decided to leave LEO Pharma for a CEO role at Union Therapeutics.
- Ends –
Contacts
Henrik Kyndlev
+45 3140 6180
hdtdk@leo-pharma.com
About LEO Pharma
The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. For more information about LEO Pharma, visit www.leo-pharma.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma and X-Chem Enter Into Discovery Research Agreement6.7.2021 08:00:00 CEST | Press release
Multi-target Collaboration to Focus on Identification of Novel Small Molecules for Anti- inflammatory Applications
Jesper Brandgaard ny formand for LEO Pharmas bestyrelse1.7.2021 13:00:00 CEST | Pressemeddelelse
Jesper Brandgaard bliver ny formand for LEO Pharmas bestyrelse. Han afløser Olivier Bohuon.
LEO Pharma announces European Commission approval of Adtralza® (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis22.6.2021 08:00:00 CEST | Press release
NOT FOR DISTRIBUTION IN THE UK OR IRELAND BALLERUP, Denmark, JUNE 22, 2021 – LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Commission (EC) has approved Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The European approval makes Adtralza the first high affinity, fully human monoclonal antibody approved to specifically bind to and inhibit the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.1,4,5
LEO Pharma initiates the first Phase 3 clinical trial with delgocitinib cream in adult patients with moderate-to-severe chronic hand eczema (CHE)18.5.2021 08:00:00 CEST | Press release
NOT FOR DISTRIBUTION IN THE UK OR IRELAND BALLERUP, Denmark, 18 May 2021 -- LEO Pharma A/S, a global leader in medical dermatology, today announced it has enrolled the first adult patient in the first of two pivotal Phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adult patients with moderate-to-severe chronic hand eczema (CHE).
LEO Pharma receives positive CHMP opinion of Adtralza® (tralokinumab) for the treatment of adults with moderate-to-severe atopic dermatitis23.4.2021 12:32:53 CEST | Press release
• If authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms1,2 • The CHMP opinion is primarily supported by data from ECZTRA 1, 2, and 3 trials included in the Marketing Authorization Application
LEO Fondet og Nordic Capital indgår nyt partnerskab, der skal styrke LEO Pharma23.3.2021 13:00:00 CET | Pressemeddelelse
Nordic Capital, en førende global investor inden for sundhedsområdet, bliver partner med LEO Fondet og træder ind i LEO Pharma som aktiv minoritetsejer, der skal understøtte LEO Pharmas rejse mod globalt lederskab inden for medicinsk dermatologi og bidrage til at accelerere innovation og vækst. LEO Fondet er fortsat virksomhedens majoritetsejer.
LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 202023.3.2021 13:00:00 CET | Press release
Ballerup, Denmark, March 23, 2021. LEO Pharma net sales recovered from COVID-19 impact during the year, reaching DKK 10.1 billion (-6%) Strategic psoriasis products Enstilar® and Kyntheum® continued to grow and gain market share. Total revenue declined 1.8% when excluding discontinued or divested products. This was offset by the impact of coronavirus lockdowns, generics in Europe and further price pressure in the US. - Revenue of Enstilar® increased 3% (+10% in Europe) to DKK 1,125 million, compared to topical market declining 2% - Revenue of Kyntheum® increased 40% to DKK 467 million compared to market growth of biologics for psoriasis of 16% Strategic projects progressed as planned while LEO Pharma ensured business continuity In response to the coronavirus pandemic, LEO Pharma successfully implemented a plan to ensure safety and corporate responsibility, continuity of supply, and continuity of strategic projects. - Supply chain and clinical trials continued uninterrupted - Introduced
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom